

Supplementary Material: Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination

Supplementary Table 1. Protection against any Omicron BA.2 reinfection and against symptomatic Omicron BA.2 reinfection associated with pre-Omicron and Omicron BA.1 primary infection (PI) with/without vaccination. 2

Supplementary Table 2. Protection against Omicron BA.2 reinfection induced by primary pre-Omicron or Omicron BA.1 infection with/without vaccination, by reinfection definition: ≥ 30 -day interval versus ≥ 90 -day interval between positive NAAT test results 3

Supplementary Figure 1. Study population 4

Supplementary Table 1. Protection against any Omicron BA.2 reinfection and against symptomatic Omicron BA.2 reinfection associated with pre-Omicron and Omicron BA.1 primary infection (PI) with/without vaccination.

Infection history and vaccination status ^a	Any Omicron BA.2 infection		Symptomatic Omicron BA.2 infection	
	Unadjusted protection (95% CI)	Adjusted protection ^b (95% CI)	Unadjusted protection (95% CI)	Adjusted protection ^b (95% CI)
Pre-Omicron PI				
Unvaccinated	36% (19, 50)	38% (19, 53)	49% (21, 68)	51% (22, 69)
1-dose vaccinated	27% (15, 38)	56% (47, 63)	73% (64, 79)	74% (66, 80)
2-dose vaccinated	48% (41, 54)	69% (64, 73)	80% (75, 84)	81% (76, 85)
3-dose vaccinated	51% (45, 56)	70% (66, 74)	81% (77, 85)	83% (78, 86)
Omicron BA.1 PI				
Unvaccinated	73% (67, 78)	72% (65, 78)	87% (80, 91)	86% (79, 91)
1-dose vaccinated	87% (75, 94)	89% (78, 95)	97% (89, 99)	97% (89, 99)
2-dose vaccinated	92% (91, 94)	96% (95, 96)	98% (97, 98)	98% (97, 98)
3-dose vaccinated	93% (92, 94)	96% (95, 97)	98% (98, 99)	98% (98, 99)
No prior infection				
Unvaccinated	Referent	Referent	Referent	Referent
1-dose vaccinated	-9% (-39, 14)	9% (-19, 31)	45% (16, 64)	43% (11, 63)
2-dose vaccinated	-17% (-29, -5)	35% (27, 42)	58% (49, 66)	61% (52, 69)
3-dose vaccinated	4% (-6, 13)	46% (40, 52)	67% (59, 73)	70% (62, 75)

^b Total number of doses administered before study inclusion regardless timing with respect to prior primary infection (before and/or after primary infection)

^a Logistic regression models adjusted for age, sex, type of employment, facility, indication for testing and epidemiological week. Exposures are compared to unvaccinated individuals without infection history.

Abbreviations: CI, confidence interval; PI, primary infection

Supplementary Table 2. Protection against Omicron BA.2 reinfection induced by primary pre-Omicron or Omicron BA.1 infection with/without vaccination, by reinfection definition: ≥30-day interval versus ≥90-day interval between positive NAAT test results


Infection history and vaccination status ^a	Omicron BA.2 infection ≥30-day definition of reinfection				Omicron BA.2 infection ≥90-day definition of reinfection			
	Cases	Controls	Unadjusted effectiveness (95% CI)	Adjusted effectiveness ^b (95% CI)	Cases	Controls	Unadjusted effectiveness (95% CI)	Adjusted effectiveness ^b (95% CI)
Pre-Omicron PI	2521	7360			2521	7360		
Unvaccinated	109	265	36% (19, 50)	38% (19, 53)	109	265	36% (18, 50)	38% (18, 53)
1-dose vaccinated	342	729	27% (15, 38)	56% (47, 63)	342	727	27% (14, 38)	57% (48, 64)
2-dose vaccinated	897	2665	48% (41, 54)	69% (64, 73)	897	2665	48% (41, 54)	69% (64, 74)
3-dose vaccinated	1173	3701	51% (45, 56)	70% (66, 74)	1173	3703	51% (44, 56)	71% (67, 75)
Omicron BA.1 PI	659	12315			470	9118		
Unvaccinated	125	727	73% (67, 78)	72% (65, 78)	91	604	77% (70, 82)	73% (65, 79)
1-dose vaccinated	9	109	87% (75, 94)	89% (78, 95)	7	84	87% (72, 94)	87% (71, 94)
2-dose vaccinated	262	5322	92% (91, 94)	96% (95, 96)	207	4290	93% (91, 94)	96% (95, 96)
3-dose vaccinated	263	6157	93% (92, 94)	96% (95, 97)	165	4140	94% (93, 95)	96% (95, 97)
No prior infection and unvaccinated	672	1043	Reference	Reference	672	1049	Reference	Reference

^a Total number of doses administered before study inclusion regardless timing with respect to prior primary infection.

^b Logistic regression models adjusted for age, sex, type of employment, facility, indication for testing and epidemiological week. Exposures are compared to unvaccinated individuals without infection history.

Abbreviations: CI, confidence interval; NAAT, nucleic acid amplification test

Supplementary Figure 1. Study population



Abbreviations: NAAT, nucleic acid amplification test